Targeting Upstream Mediators and the Airway Epithelium With Next-Generation Biologics Evaluation (ID: i827a) Question Title * 1. Sara, a 36-year-old female, presents on 6-month follow-up after initiating IL-5 antibiotic and continuing high-dose ICS. Baseline eosinophils were 374/µL and FeNO was 51 ppb. Her IgE level was 25 IU/ml and allergy skin tests were negative. She has no notable comorbidities or atopic history. She was diagnosed with asthma at age 27. She continues to experience symptoms 2-3x/week with 1 exacerbation in the last 6 months and is concerned about continued impact to daily activities. What would be the most appropriate next step? Continue the anti-IL-5 biologic and reassess in 3-6 months Switch to a different IL-5 biologic Switch to anti-IL-4 biologic Switch to anti-IgE biologic Discontinue biologic and prescribe OCS Question Title * 2. How many patients with severe asthma do you manage per week? 1 to 10 11 to 25 26 to 50 I am not directly involved in patient care Question Title * 3. After participating in this activity, how confident are you in the management of patients with severe asthma in your practice? Very confident Confident Neutral Little confidence No confidence Question Title * 4. How committed are you to making changes in your practice based on your participation in this activity? Very committed Committed Neutral Not committed I do not plan to make changes If not committed or do not plan to make changes, please indicate reason Question Title * 5. Which of the following best describes the impact of this activity on your performance? I gained new strategies/skills/information I can apply to my area of practice I need more information before I can change my practice My practice is already consistent with the information presented This activity will not change my practice Question Title * 6. Which new strategies/skills/information will you apply to your area of practice? Please select all that apply. Improved awareness of the unmet treatment needs in severe asthma Better understanding of the limitations of conventional biologic therapies Increased knowledge of the benefit of targeted therapeutic options for patients with severe asthma Increased awareness of the primary upstream cytokines involved in severe asthma Improved knowledge of the role of specific epithelial alarmins in inducing symptoms of severe asthma Better able to appropriately incorporate therapies that target alarmins into individualized treatment regimens to meet the unmet needs of patients with severe asthma Increased awareness of investigational and newly approved anti-alarmin therapies Increased knowledge of clinical trial data for anti-alarmin agents and how to apply this data to clinical care Improved ability to select the optimal anti-alarmin therapy for the individualized treatment of patients with severe asthma Question Title * 7. What barriers do you see to making changes in your practice? Please select all that apply. Lack of knowledge regarding evidence-based strategies Lack of convincing evidence to warrant change Lack of time/resources to consider change Insurance, reimbursement, or legal issues Conflicting guidelines or evidence Patient compliance and/or patient resource barriers Other (please explain) Question Title * 8. Please rate your level of agreement by checking the appropriate rating.Jonathan Corren, MD, effectively: Strongly Agree Agree Neutral Disagree Strongly Disagree Presented the Material Presented the Material Strongly Agree Presented the Material Agree Presented the Material Neutral Presented the Material Disagree Presented the Material Strongly Disagree Avoided Commercial Bias Avoided Commercial Bias Strongly Agree Avoided Commercial Bias Agree Avoided Commercial Bias Neutral Avoided Commercial Bias Disagree Avoided Commercial Bias Strongly Disagree Question Title * 9. Please rate your level of agreement by checking the appropriate rating.Nicola A. Hanania, MD, MS, effectively: Strongly Agree Agree Neutral Disagree Strongly Disagree Presented the Material Presented the Material Strongly Agree Presented the Material Agree Presented the Material Neutral Presented the Material Disagree Presented the Material Strongly Disagree Avoided Commercial Bias Avoided Commercial Bias Strongly Agree Avoided Commercial Bias Agree Avoided Commercial Bias Neutral Avoided Commercial Bias Disagree Avoided Commercial Bias Strongly Disagree Question Title * 10. Please rate your level of agreement by checking the appropriate rating.The educational activity: Strongly Agree Agree Neutral Disagree Strongly Disagree Met the identified learning objectives Met the identified learning objectives Strongly Agree Met the identified learning objectives Agree Met the identified learning objectives Neutral Met the identified learning objectives Disagree Met the identified learning objectives Strongly Disagree Enhanced my current knowledge base Enhanced my current knowledge base Strongly Agree Enhanced my current knowledge base Agree Enhanced my current knowledge base Neutral Enhanced my current knowledge base Disagree Enhanced my current knowledge base Strongly Disagree Addressed my most pressing questions Addressed my most pressing questions Strongly Agree Addressed my most pressing questions Agree Addressed my most pressing questions Neutral Addressed my most pressing questions Disagree Addressed my most pressing questions Strongly Disagree Promoted improvements or quality in health care Promoted improvements or quality in health care Strongly Agree Promoted improvements or quality in health care Agree Promoted improvements or quality in health care Neutral Promoted improvements or quality in health care Disagree Promoted improvements or quality in health care Strongly Disagree Was scientifically rigorous and evidence based Was scientifically rigorous and evidence based Strongly Agree Was scientifically rigorous and evidence based Agree Was scientifically rigorous and evidence based Neutral Was scientifically rigorous and evidence based Disagree Was scientifically rigorous and evidence based Strongly Disagree Avoided commercial bias or influence Avoided commercial bias or influence Strongly Agree Avoided commercial bias or influence Agree Avoided commercial bias or influence Neutral Avoided commercial bias or influence Disagree Avoided commercial bias or influence Strongly Disagree Question Title * 11. As a result of your participation in this activity, what is the one change you are most likely to implement in your practice? Question Title * 12. Please list any clinical issues/problems within your scope of practice you would like to see addressed in future severe asthma educational activities: Question Title * 13. If you indicated that you perceived commercial bias or influence, please describe: Done